



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOx 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/897,042	07/03/2001		Rudolf Valenta	1614-0251P	5581
24256	7590	07/19/2004		EXAMINER	
DINSMORE	& SHO	HL, LLP	NOLAN, PATRICK J		
1900 CHEMED CENTER 255 EAST FIFTH STREET				ART UNIT	PAPER NUMBER
CINCINNATI			1644		

DATE MAILED: 07/19/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(	(s)			
	09/897,042	VALENTA	VALENTA ET AL.			
Office Action Summary	Examiner	Art Unit				
	Patrick J. Nolan	1644				
The MAILING DATE of this communication ap	ppears on the cove	sheet with the corresponde	ence address			
Period for Reply	VIO OFT TO EVI	DIDE AMONTH(S) EDOM				
A SHORTENED STATUTORY PERIOD FOR REPI THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a report of the period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by statue Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, how ply within the statutory min d will apply and will expire te cause the application to	ever, may a reply be timely filed  nimum of thirty (30) days will be conside  SIX (6) MONTHS from the mailing date o become ABANDONED (35 U.S.C. §	133).			
Status						
1) Responsive to communication(s) filed on 11	<u>May 2004</u> .					
	is action is non-fin					
3) Since this application is in condition for allow						
closed in accordance with the practice under	Ex parte Quayle,	1935 C.D. 11, 453 O.G. 210	3.			
Disposition of Claims						
4)  Claim(s) <u>24-31</u> is/are pending in the applicating 4a) Of the above claim(s) is/are withdrest 5)  Claim(s) is/are allowed.  6)  Claim(s) <u>28,30 and 31</u> is/are rejected.  7)  Claim(s) <u>25-27 and 29</u> is/are objected to.  8)  Claim(s) are subject to restriction and the subject to restrict th	awn from conside					
Application Papers						
9)☐ The specification is objected to by the Examir						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
·		, attached officer to the first				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreignal All b) Some * c) None of:  1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the prapplication from the International Bure * See the attached detailed Office action for a list	nts have been rec nts have been rec iority documents h au (PCT Rule 17.	eived. eived in Application No ave been received in this N 2(a)).				
Attachment(s)	<b>∧</b> □	Intention Summan (DTO 412)				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) [_	Paper No(s)/Mail Date				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date	/O) / ;;;;;	5) Notice of Informal Patent Application (PTO-152) 6) Other:				

Art Unit: 1644

1. Claims 25-31 are pending.

2. Applicant's after-final received 5-11-04 has been entered. A new non-final rejection is set forth below.

## Claim rejections 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 28 and 30-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ferreira et al., newly cited, in view of U.S. Patent 4,269,764, and U.S. Patent 6,126,939, both of record.

Ferreira et al., specifically teaches the use of recombinantly produced non-anaphylactic Bet v 1 proteins in the treatment of Bet v1 allergy, see pages 606-607 and 600 in particular.

The claimed invention differs from the prior art teachings by using a polymerized allergen that has a peptide linker that is hydrophilic. However, the '764 patent teaches that polymerization of allergens produces immunogenic allergens that have markedly reduced allergenicity (column 1-2, in particular). The markedly reduced allergenicity of the polymerized allergen would have the expected property of being non-anaphylactic, since a heightened allergic response is a prerequisite of allergen mediated anaphylaxis and, the '939 patent teaches immunogens comprising polymers of peptides linked by a hydrophilic oligopeptide linker (i.e. "a

Art Unit: 1644

short stretch of alanine residues" which are hydrophilic) to treat or ameliorate inflammation associated with allergic reactions; see column 9, paragraphs 2-4; and column 11, paragraph 2 in particular).

One of ordinary skill in the art at the time the invention was made would have been motivated to polymerize the Bet v 1 allergen, as taught by the Ferreira et al., because polymerized allergens show reduced allergenicity as taught by the '764 patent and use peptide linkers to polymerize a protein using hydrophilic amino acids, as taught by the '939 patent because the polymerized allergens linked by hydrophilic amino acids show reduced allergenicity as taught by the '939 patent. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole is <u>prima facie</u> obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

- 4. Claims 29 and 25-27 are objected to as being dependent upon rejected claims.
- 5. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.
- 6. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is 571-272-0847.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at 571-272-0841.

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

July 13, 2004